Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial-Reference-Cited by-同舟云学术

Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial

Published:2020-04-18 Issue:8 Volume:69 Page:1663-1672
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Khammari Amir,Nguyen Jean-Michel,Leccia Marie-Thérèse,Guillot Bernard,Saiagh Soraya,Pandolfino Marie-Christine,Knol Anne-Chantal,Quéreux Gaëlle,Chiffolettau Anne,Labarrière Nathalie,Dréno Brigitte

Funder

LABoratoires d’EXcellence IGO

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-020-02572-1.pdf

Reference36 articles.

1. Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463–482

2. Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J (2016) Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe—a systematic review of the literature. Clin Epidemiol 8:109–122

3. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356